Brand Name :
Sanctura, Regurin, Sanctura XR
Synonyms :
trospium
Class :
Anticholinergic Agent and Urinary antispasmodics
Brand Name :
Sanctura, Regurin, Sanctura XR
Synonyms :
trospium
Class :
Anticholinergic Agent and Urinary antispasmodics
Dosage Forms & Strengths
Tablet
20mg
Capsule-ER
60mg
Safety and efficacy not established
Refer adult dosing
it may increase the effect of anticholinergic agents
it may increase the effect of anticholinergic agents
it may increase the constipating effect of eluxadoline
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
May enhance the anticholinergic effect of Anticholinergic Agents
fluticasone furoate umeclidinium and vilanterol
umeclidinium may enhance the anti-cholinergic effect of anti-cholinergic agents
anticholinergic agents decrease the efficacy of levosulpride
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the effect of constipation of eluxadoline
may increase the anticholinergic effect of anticholinergic agents
may enhance the constipation effect
may enhance the activity of each other
may enhance the ulcerogenic activity
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
may enhance the effect of each other
may increase the anti-cholinergic effect
anticholinergic agents increase the effect of cimetropium
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
anticholinergic agents may enhance the adverse/toxic effect of opioid agonists
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of anticholinergic agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
they increase the toxicity of opioid agonists
they increase the toxicity of opioid agonists
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of acetylcholinesterase Inhibitors
may diminish the therapeutic effect of gastrointestinal agents
may diminish the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of anticholinergic agents
may enhance the adverse/toxic effect of other anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors may diminish the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
acetylcholinesterase Inhibitors reduce the therapeutic effect of anticholinergic Agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anticholinergic agents increase the toxicity of topiramate
may enhance the tachycardiac effect
may enhance the tachycardiac effect
may increase the anti-cholinergic effect
may increase the anti-cholinergic effect
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may enhance the anti-cholinergic effect
may enhance the anti-cholinergic effect
may increase the toxic effects of opioid agonists
may increase the analgesic effect of opioid agonist
may increase the anti-cholinergic effect
may increase the toxic effects of opioid agonists
may increase the toxic effects
may increase the toxic effects of CNS depressants
Adverse drug reactions:
Frequency Defined
>10%
Dry mouth
1-10%
Rash
Dyspepsia
Abdominal pain
Constipation
Tachycardia
Constipation
Dry eyes
Dyspepsia
Flatulence
Urinary retention
Urinary tract infection
Nasopharyngitis
Nasal dryness
Post-marketing Reports
Gastritis
Palpitations
supraventricular tachycardia
chest pain
syncope
hypertensive crisis
Stevens-Johnson syndrome
anaphylactic reaction
angioedema
Dizziness
hallucinations
somnolence
delirium
Pregnancy warnings:
Pregnancy Category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: trospium
Pronunciation: tros-PEE-um
Why do we use trospium?
trospium is an anticholinergics agent which acts as a Urinary antispasmodic. It is used to treat overactive bladder, symptoms of urinary urgency, incontinence, and frequency.